In Brief
INTRODUCTION
Adaptive immune responses are initiated by T cell receptor (TCR) recognition of peptides presented by major histocompatibility molecules (pMHC). TCR engagement with an agonist pMHC leads to phosphorylation of CD3 immunoreceptor tyrosine-based activation motifs (ITAMs), initiating a cascade of downstream signaling that results in T cell activation (Chakraborty and Weiss, 2014) . Despite the low 3D affinity (K D $1-100 mM) of the TCR-pMHC interaction, the potency of the T cell response has been shown to generally reflect the strength, or duration, of a particular interaction (Allison et al., 2016; Gottschalk et al., 2012; Govern et al., 2010) . Studies using altered peptide ligands (APLs) found that TCR signaling is strongly correlated with TCR-pMHC 2D binding affinity, kinetics, and 2D confinement time (Aleksic et al., 2010; Huang et al., 2010; Huppa et al., 2010; Klammt et al., 2015) . However, the 3D affinities of strong and weak agonist ligands for a single T cell clone can be similar and, at times, overlapping (Baker et al., 2000; Degano et al., 2000; Stone et al., 2009) or even uncorrelated (Kalergis et al., 2001; Kersh et al., 1998; Zehn et al., 2009 ). The molecular parameters underlying these discrepancies have remained elusive. TCR signaling is influenced by parameters other than the affinity of TCR for pMHC (Adams et al., 2011; Kim et al., 2009; Su et al., 2016) . For example, force-dependent interactions are a characteristic of agonist pMHC ligands (Feng et al., 2017; Hong et al., 2015; Kim et al., 2012; Liu et al., 2014) . TCRs form catch bonds with agonist ligands, during which the bond lifetime of the interaction extends under force (Hong et al., 2015; Liu et al., 2014 Liu et al., , 2016 . Exclusion of the phosphatase CD45 from membrane contacts initiates TCR signaling independent of pMHC ligands (Chang et al., 2016) . Several studies have described T cell clones that engaged with pMHC yet were unresponsive when simulated by the isolating peptide (Adams et al., 2011; Bentzen et al., 2016; Moon et al., 2007; Rubio-Godoy et al., 2001; Yu et al., 2015) .
The existence of binding but non-activating pMHC ligands presents a unique opportunity to probe the underlying molecular mechanism of the TCR triggering process from an alternative vantage point. Here, we study examples of naturally occurring non-agonist TCR-pMHC interactions in order to isolate properties responsible for uncoupling binding from signaling. We found that frequent occurrences of non-agonist TCR-pMHC interactions occur in vivo. Using complementary methodologies, we examined two TCRs specific for HLA-B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ), one of which exhibited impaired signaling despite exhibiting a robust binding interaction (Ueno et al., 2004) . Selections on a pMHC yeast display library identified stimulatory peptide ligands for the signaling-refractive TCR that differed by as little as a methylene group. Detailed biophysical characterization of agonist and non-agonist interactions with the same TCR revealed two parameters that correlated with potent signaling: formation of catch bonds and segregation of CD45. We used steered molecular dynamics simulations based on crystal structures of the agonist and non-agonist complexes to develop a molecular model of TCR-pMHC catch bond formation. Catch bonds represent a net gain of molecular interactions under force, revealing an additional level of dynamic diversity built-in as a proofreading mechanism to link TCR recognition and subsequent activation. Collectively, our study revealed a triggering mechanism by which TCR ligation and activation can be coupled or decoupled to regulate TCR ligand discrimination.
RESULTS

Occurrence of T Cells that
Engage pMHC yet Are Not Activated Several studies have described T cell clones that bind to fluorescently labeled class I and class II pMHC tetramers yet are unresponsive to peptide stimulation (Bentzen et al., 2016; Moon et al., 2007; Su et al., 2013) . We therefore explored the prevalence of this phenomenon in the natural human T cell repertoire. T cells were stained with fluorescent pMHC tetramers, sorted to single cells, and expanded non-specifically ex vivo. To confirm specificity, these clones were re-stained with the pMHC tetramer and stimulated with the specific peptide to assess responsiveness (Figure 1A) . We identified both responsive and non-responsive T cell clones isolated with HLA-DR4-HIV(Gag [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] ) fluorescent tetramers. We compared a pMHC-responsive clone, TCR6 top) , to a non-responsive clone, TCR11 bottom) . While both clones bound their cognate pMHC-tetramer (Figure 1B) , only TCR6 proliferated, secreted cytokines, and downregulated TCR in response to stimulation with DR4-HIV(Gag [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] ). TCR11 failed to mount a response ( Figures 1C-1E ). Both T cell clones downregulated TCR and proliferated in response to non-specific TCR stimulation (Figures 1E and S1) . We confirmed that the non-stimulatory response was TCR mediated by transducing TCR6 or 11 into a TCR ab-deficient cell line. Both T cell lines robustly secreted IL-2 in response to anti-CD3 (OKT3) stimulation; however, there was a substantial difference in IL-2 secretion upon stimulation with DR4-HIV(Gag [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] ) (Figure S2) .
We surveyed T cell clones initially isolated through pMHC tetramer binding and sorting using HLA-A2*01-restricted hepatitis C virus (HCV) NS3 variant peptides (KLVALGINAV, L5N, and L5M) as well as the HY self-antigen (FIDSYICQV) (Yu et al., 2015) . While most of the clones in the datasets were capable of activation, a fraction (ranging from 15% to 72%) were tetramer positive yet did not produce an antigenspecific response (Figures 1J and S1) . Taken together, these data indicated that pMHC binding does not uniformly predict T cell activity.
In order to determine the molecular basis of this phenomenon, we focused on a pair of HLA-B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] )-specific TCRs, one of which (TCR55) appeared to have decoupled TCR-pMHC binding and signaling (Ueno et al., 2004 ). When we transduced responder (TCR589) or impaired-responder (TCR55) TCRs into a TCR ab-deficient cell line, both T cell lines were stained by the B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) fluorescent tetramers, as previously reported ( Figure 1K ) (Ueno et al., 2004) . The TCR589-transduced cell line showed dose-dependent secretion of IL-2 in response to peptide-pulsed APCs, while the TCR55-transduced cell lines failed to secrete detectable IL-2 for all peptide concentrations tested (Figure 1L) . When the TCR55 and TCR589 cell lines were stimulated non-specifically with OKT3, both T cell lines responded similarly (Figure S1 ). ) with affinities of 17 mM and 4 mM 3D K D (Figure 2B) , respectively, as determined by surface plasmon resonance (SPR). TCR589 had a slower k off (0.71 s À1 ) than TCR55, whose k off exceeded the limit of detection (Figures 2B and 2E) . Both 3D K D values and kinetic rate constants were within typical range of 3D binding affinities and kinetics measured for agonist peptides (Stone et al., 2009) . We also measured the 3D affinity of MHC class II DR4-HIV(Gag [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] )-specific TCRs. Surprisingly, the non-stimulatory TCR11 bound with a higher 3D affinity (1 mM K D ) than the stimulatory TCR6 (10 mM K D ) ( Figure S2 ). We sought to determine whether TCR55 on cells engaged pMHC molecules in the context of lipid bilayers. We imaged the B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] )-TCR55 and TCR589 interactions in hybrid live-cell-supported lipid bilayer junctions to assess (D) IL-2 and IFNg production in response to HIV(Gag [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] . (E) TCR downregulation in response to HIV stimulation (red), CD3-CD28 beads (blue), PHA (gray). (B-E) Top: TCR6; bottom: TCR11. (F and G) Representative HLA-A2-HCV(NS3) tetramer staining (F) and functional response (G) by CD107a in T cell clones. (H and I) HLA-A2-HY tetramer staining (H) and functional response (I) by CD107a. (F-I) Staining or stimulation with irrelevant pre-proinsulin (PPI) peptide represented in gray. (J) Summary of frequency of non-stimulatory clones from (Yu et al., 2015) . (K) B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) tetramer staining (100 nM) of transduced cell lines expressing TCR55 (orange), TCR589 (blue), or untransduced (gray). (L) IL-2 secretion by TCR55 (orange) or TCR589 (blue) transduced T cells. Representative data (n = 3) is shown as mean ± SD of technical triplicates. See also Figure S1 . possible differences in the interaction dwell times. The supported membrane was functionalized with fluorescently labeled B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) (Figure S3 ) and ICAM1. Using total internal reflection fluorescence (TIRF) microscopy, pMHC molecules were unambiguously resolved in complex with cell-surface-expressed TCRs ( Figure 2C ; Video S1). TCR55 and TCR589 bound to ) with similar mean dwell times of 10.1 ± 2.0 s and 8.7 ± 2.1 s, respectively ( Figures 2D and 2E ), comparable to the dwell times previously reported for 5cc7 -I-E k (MCC) and AND-I-E k (MCC) (O'Donoghue et al., 2013) .
Non-stimulatory Interaction Parameters Are Similar to Agonist Interactions
Structural Analysis of Agonist versus Non-agonist Interactions
To identify potential structural differences in the TCR B35-HIV (Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) interaction, we determined the crystal structures of TCR589 and TCR55 in complex with B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) ; Table S1 ). The structure of TCR55 complexed with B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) was also reported recently (Shi et al., 2017) . Although TCR55 is translated 8 Å toward the B35a1 helix compared to TCR589, the overall docking geometries of TCR589 and TCR55 are similar and unremarkable (Figures 2G and S3) . We see no substantial differences in the conformations of the constant regions that would indicate differential allostery correlating with signaling. TCR55 and TCR589 do not share Va, Vb, or CDR3 sequences and exhibited distinct binding chemistries to B35-HIV(Pol 448-456 ) ( Figure S3 ; Figure 2H ). TCR589 makes the majority of its contact with the Pol 448-456 peptide through its CDR3 loops (Table S2) . While TCR55 makes key salt-bridges with Pol 448-456, the majority of the binding interface is from CDR1/2a interactions with the B35a1 helix and CDR3b interactions with the B35a2 helix ( Figures 2G, 2H , and S3; Table S2 ).
TCR55 Exhibits Impaired T Cell Signaling
To analyze the functional capacity of these two T cell clones, we traced the activation defect within the signaling cascade. The HIV ) peptide was applied to the B35-expressing cell line KG-1 and SKW3 T cells transduced with TCRs were probed for the surface-expressed activation marker CD69. The TCR589-expressing cell line showed dose-dependent upregulation of CD69; however, the TCR55-expressing cells failed to upregulate CD69, consistent with the IL-2 secretion-defective phenotype previously observed (Figures 1L and 3A) . While both TCRs showed robust ERK1/2 phosphorylation (pERK) in response to OKT3 stimuli, only the TCR589 transduced cell line responded to the HIV(Pol 448-456 ) peptide ( Figures 3B, 3C , and S3).
We assessed early stages of TCR triggering by examining calcium signaling dynamics. We imaged TCR55-or TCR589-expressing cells labeled with Fluo-4 and activated by coverslips coated with B35-HIV(Pol 448-456 ) monomers, or OKT3. Both T cell clones responded to OKT3 stimulation ( Figure S3) ; however, only 12% ± 3% TCR55-expressing cells fluxed calcium in response to ) stimulation, as compared to 51% ± 4% of TCR589-expressing T cells ( Figures 3D and 3E) . Furthermore, the TCR589-expressing cells exhibited a substantial and rapid increase in calcium followed by a decay, classified as a type-a calcium response and indicative of successful TCR triggering (Liu et al., 2014) . In contrast, TCR55-expressing cells showed a type-b calcium signal, characterized by intracellular calcium either remaining at baseline or increasing only slightly ( Figures 3D, 3E , and S3). These results are consistent with calcium signaling observed for the DR4-HIV(Gag) specific TCRs, in which 70% ± 2% of TCR6-expressing cells were triggered compared to 31% ± 8% of TCR11-expressing cells when stimulated with DR4-HIV(Gag) (Figure S2) .
Upon TCR triggering, ZAP70 is recruited to phosphorylated ITAMs. We used spinning disc TIRF microscopy to observe ZAP70 recruitment in non-agonist and agonist TCR-pMHC interactions. TCR55-and TCR589-expressing cell lines were lentivirally transduced to express ZAP70-GFP in order to visualize intracellular ZAP70 localization. Cells were examined while in contact with supported lipid bilayers (SLBs) functionalized with B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) and ICAM1. TCR589-expressing cells exhibited canonical ZAP70 recruitment: ZAP70 clusters centripetally moved toward the center of the cell (Figure 3F , bottom; Video S2). The TCR55-expressing cells exhibited a uniform distribution of ZAP70 throughout the cytoplasm upon interaction with the SLB (Figure 3F , top; Video S2). The non-agonist signaling defect thus occurred at a membrane-proximal stage.
TCR55 Recognizes Multiple Peptides Related to HIV(Pol 448-456 )
We undertook a gain-of-function approach to isolate the molecular origins of the signaling defect exhibited by TCR55. We developed an HLA-B35 yeast display library to identify agonist ligands for TCR55 that would allow us to directly compare TCR55 in both ''off'' and ''on'' states ( Figure S4) . The B35 peptide library was designed as a 9-mer (the length of Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) in which P1 and P3-P8 were randomized using NNK codons, and the anchor residues, P2 and P9, encoded known B35 anchors ( Figure 4A ). We generated a pool of approximately 2 3 10 8 unique transformants on which we performed selections with multimerized TCR55 Figure S3 , Tables S1 and S2 , and Video S1.
( Figure 4B ). After iterative rounds of selections, we obtained yeast clones bearing pMHC molecules that bound to TCR55 (Figure 4B) . Each round of the selected pool was deepsequenced to recover the identities of enriched peptides (Figures 4C, 4D, and S4) . TCR55 recognized a peptide sequence kernel resembling the HIV(Pol 448-456 ) peptide ( Figure 4D ). The TCR-facing residues P1 and P5 were essentially invariant, presenting valine and glutamic acid, respectively ( Figure 4D ). The selection of P5-Glu reflected its observed structural importance in TCR55's ability to bind to B35-HIV(Pol 448-456 ) (Figure 2) . Additionally, at P6, an MHC-facing residue, aspartic acid was highly preferred over the wildtype glutamic acid ( Figure 4D ). For the remaining TCR-facing residues, P4 and P8, there were no significant preferences. The selection data revealed 9-mer peptides composed of a P1V, P5E, and P6D readily bound to TCR55. Using Hamming . Data shown as mean ± SD for n = 2 independent experiments (right). Related to Figure S3 and Video S2.
distance-based clustering, we identified one primary family of peptides (differing by 1-4 amino acids) that encompassed the most enriched ligands ( Figure S4 ).
3D TCR/pMHC Affinity Is Poorly Correlated with Signaling Outcome
We synthesized 50 peptides derived from the library and tested their stimulatory potential on T cell lines transduced with TCR55.
We found a wide range of potencies of the peptides discovered by the B35 library, ranging from full agonism to partial agonism to no detectable signaling ( Figures 5A-5C and S5). The peptides that elicited these disparate signaling outcomes were remarkably similar in sequence. We chose a set of 15 peptides that displayed varied signaling capacity to further examine the relationship between 3D affinity and potency. TCR55 bound to the various pMHCs of interest with a range of K D s from 0.5 mM to >80 mM ( Figure 5D ). All ligands showed immeasurably fast, box-like kinetics similar to the TCR55-HIV(Pol 448-456 ) interaction (see https://doi.org/10.17632/sgff3j9sbg.1).
The compilation of the 3D affinity and potency data indicated that, with the exception of the highest-affinity pMHC ligands, the affinity of a given ligand for TCR55 was poorly predictive of T cell activation. While very high-affinity (< 2 mM) ligands elicited uniformly potent activation of TCR55 ( Figures 5D and S5 , salmon background), intermediate-and low-affinity ligands (5 to > 80 mM; Figure S5 , aqua background) exhibited highly variable signaling responses (Figures 5D and S5; see https://doi. org/10.17632/sgff3j9sbg.1). We found a weak correlation between EC 50 and K D for the set of pMHCs for which an EC 50 could be calculated (r 2 = 0.098). Ligands with similar EC 50 exhibited affinities spanning two orders of magnitude. Within that range, we found agonist peptides (e.g., SQL) that were of similar affinity to HIV(Pol 448-456 ) ( Figures 5D and S5 ).
TCR55 Has Virtually Identical Structure Bound to
Agonist and Non-agonist pMHC Ligands A high-potency agonist ligand, Pep20, had two conservative substitutions relative to the HIV peptide, which converted the peptide from a non-agonist to a potent agonist: P1-Ile to Val and P6-Glu to Asp. P1 makes scant contact with TCR55 in the crystal structure (Figure 2) , and P6 is an MHC-buried residue. These mutations rescued Zap70 clustering, ERK-phosphorylation, and CD69 upregulation (Figures 5A and S6; see https:// doi.org/10.17632/sgff3j9sbg.1) and increased the 3D affinity to 500 nM K D (Figure S5) . Using this strong agonist, we assessed whether HIV(Pol 448-456 ) could be an antagonist peptide. Pep20-induced activation was not influenced by the presence HIV(Pol 448-456 ), suggesting it is not an antagonist ( Figure S6 ) (Bertoletti et al., 1994) . Additionally, the 2D dwell time of TCR55 in complex with B35-Pep20 showed a longer halflife of 11 ± 1.2 s ( Figure S6 ; see https://doi.org/10.17632/ sgff3j9sbg.1) compared to the dwell time of 10.1 ± 2.0 s for TCR55-B35-HIV(Pol 448-456 ) (Figure 2 ). We determined the crystal structure of TCR55 in complex with B35-Pep20 at 1.8 Å and found no significant differences in the structure of TCR55, or in the docking footprint of the pMHC-TCR complex compared to the non-agonist complex ( Figures  6A and 6B ). The principal differences between the TCR55 B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) and TCR B35-Pep20 complexes involve the MHC-facing P6 position of the peptide that is inserted into the B35 C-pocket, hydrogen bonding to Arg97. In the B35-Pep20, the P6-Asp, which has one less methelyne group, forms an additional hydrogen bond to B35-Tyr74 ( Figure S6 ).
Strength of TCR Signaling Correlates with Ability to Exclude CD45
The kinetic segregation hypothesis posits that exclusion of the phosphatase CD45 from the early T cell-APC contacts facilitates TCR triggering (Davis and van der Merwe, 2006). We therefore compared CD45 exclusion by our diverse peptide ligands in a cell-free system using giant unilamellar vesicles (GUVs) to eliminate effects of signaling in live cells (e.g., actin reorganization) (Carbone et al., 2017) . GUVs functionalized with TCR and CD45, to mimic the T cell membrane, were incubated with SLBs functionalized with a pMHC of interest ( Figure S6 ). Fluorescent Fabs were used to spatially resolve the CD45 molecules' location. Using TIRF microscopy, we interrogated CD45 exclusion of the agonist interaction TCR589-HIV(Pol 448-456 ) and two agonist interactions for TCR55 induced by ligands identified from the yeast display library: the high-affinity Pep20 and SQL (K D = 12.5 mM), a ligand of similar affinity to HIV ). TCR589-HIV(Pol 448-456 ), TCR55-Pep20, and TCR55-SQL excluded CD45 with varying degrees of efficiency (92%, 89%, and 65%, respectively), whereas for TCR55-HIV (Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ), only 10% of GUVs excluded CD45 ( Figures 6C and  6D ). Thus, we observed that the extent of CD45 segregation correlated with the ability to induce robust signaling.
Non-agonist pMHC Ligands Form Slip Bonds with TCR55
The functional potency of TCR-pMHC interactions has been shown to correlate with catch bond formation, whereby force prolongs the bond lifetime (Hong et al., 2015; Liu et al., 2014 Liu et al., , 2016 . We analyzed the in situ 2D affinity of stimulatory and non-stimulatory TCR-pMHC interactions using a single molecule adhesion frequency assay ( Figure S6 ). To eliminate the contribution of co-receptor binding, we used a CD8
À/À T cell line to measure 2D affinities. Both TCR589-and TCR55-B35-HIV(Pol 448-456 ) interactions have 2D affinities consistent with other agonist TCR-pMHC interactions; however, TCR589-B35-HIV(Pol 448-456 ) has a comparatively higher 2D affinity ( Figure S6 ) (Adams et al., 2011; Hong et al., 2015; Huang et al., 2010; Liu et al., 2014) . We next measured the single-molecule bond lifetime of TCRpMHC interactions under conditions of force using a Biomembrane Force Probe (BFP) bond lifetime assay ( Figure 6E ). A range of forces was applied via a pMHC engaged with TCRs expressed in a CD8+ cell line. The bond lifetime of the agonist interaction of TCR589 with B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ) increased in response to increasing force, reaching a maximum at 10.7 pN, followed by a steady decrease thereafter, suggestive of a catch bond ( Figure 6F ). In contrast, the bond lifetime of TCR55 to B35-HIV(Pol 448-456 ) decreased monotonically under force, characteristic of a slip bond ( Figure 6G ). We extended this approach to the high-affinity Pep20 and affinity-matched agonist SQL ( Figures  5D and S5 ). Similar to the agonist interaction of TCR589-B35-HIV(Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ), the bond lifetimes of TCR55 with agonist pMHCs increased under force, indicating the formation of catch bonds, with peak bond lifetimes for Pep20 and SQL occurring at 13.6 pN and 6.58 pN, respectively ( Figures 6H and 6I ). These results showed that discrimination of affinity-matched agonist and non-agonist peptides recognized by the same TCR correlated with catch bond formation for the former and slip bonds for the latter.
We additionally applied the BFP assay to the TCR6-and TCR11-DR4-HIV(Gag 164-183 ) interactions. Again, the agonist TCR6-DR4-HIV(Gag 164-183 ) lifetimes increased under force, forming a catch bond, whereas the high-affinity non-stimulatory TCR11-DR4-HIV(Gag 164-183 ) bond lifetime decreased under force, forming a slip bond ( Figure S2 ).
Molecular Dynamics Simulation of TCR-pMHC CatchBond Formation
To investigate the molecular basis of catch-or slip-bond formation during TCR-pMHC disengagement, we created a dynamic molecular model to explore the differences between the TCR55-B35-Pep20, HIV, and SQL antigens using molecular dynamics (MD) simulations. We first determined free energy minima by enhanced conformational sampling, then we sheared the center of mass of TCR Vab in six directions relative to the MHC (see https://doi.org/10.17632/sgff3j9sbg.1; Method Details). For shear in the ±x and ±y directions, the critical shear force was $40 kcal/(mol$Å ). We observed multiple catch bonds for the two agonists (Pep20 and SQL) in all four directions but no catch bonds for the non-agonist (HIV) in any direction ( Figure 7D ). For tension or compression in the ±z directions ( Figure S7 ), no bonds broke under forces up to the critical shear stress in the ±x and ±y directions, and the critical tensile force was $50 kcal/(mol$Å ), suggesting that the applied force will resolve in the shear ±x and ±y directions (Feng et al., 2017) . To examine catch bond versus slip bond formation in atomic detail, we highlight TCR dissociation in the +x shear direction, where catch bonds were formed for both Pep20 and SQL . Catch bond 1 (red) represented a reorganization of interactions between CDR2a-Glu55 and the B35a2 helix. At x = 23 Å , Glu55 broke with Arg157 and formed a ''rescue'' salt bridge with Arg151. For catch bond 2 (blue), Glu52 formed a new salt-bridge with B35-Arg79 (x = 23 Å ) while maintaining its interaction with Arg75 until x = 32.3 Å . Catch bond 3 (green), formed an additional salt bridge between CDR3b-Arg96 and P5-Glu at x = 21 Å , adding to the initial interaction of CDR3b-Arg94 and P5-Glu. The original bond was maintained until x = 35 Å , and the new salt bridge broke at x = 38.5 Å . Catch bond 4 (purple) represented interactions that were not present in the starting structure. A hydrogen bond between CDR1a-Ser31 and P4-Thr was formed immediately upon shearing and was replaced by the CDR1a-Trp30 and P4-Thr hydrogen bond at x = 19 Å . Both bonds broke at x = 26.5 Å but were regained at x = 31 Å and lifted the N terminus of the peptide. The water-bridged hydrogen bond between CDR1a-Trp30 and P4-Thr was maintained even at x = 50 Å (Figures 7A, 7B and S7; Video S3) .
MD simulations of TCR55 dissociation from B35-HIV yielded four molecular slip bonds, in which the original interactions ruptured during the shearing process and no new interactions were formed (Figures 7A, 7B and S7; https://doi.org/10.17632/ sgff3j9sbg.1; Video S4). For slip bond 4, a short-lived hydrogen bond between CDR1a-Trp30 and P4-Thr existed in the range x = 22-25 Å . The dissociation trajectory can be described as slip bond 1 breaking first at x = 20 Å , followed by the formation of the transient hydrogen bond. At x = 26 Å , slip bond 3 broke, and lastly, slip bond 4 broke at x = 27.5 Å .
Simulations of TCR55 dissociation from the affinity-matched agonist SQL peptide revealed the formation of three catch bonds (Figures 7C and S7; Video S5) . Three of these catch bonds were similar to catch bonds 1-3 of the Pep20 system, while catch bond 4 was absent.
We found two instances where conservative mutations between Pep20 and HIV led to differences in dissociation dynamics relevant to their distinct signaling capacities ( Figure S7 ). First, TCR interactions with P4 caused the N terminus of the peptide to lift up from B35 during dissociation. The lifting was initially blocked by the B35a1-Arg75 interaction ( Figure S7 ). For HIV, P1-Ile posed a steric constraint and limited the N-terminal lift, thus preventing catch bond 4 formation. In Pep20, the less bulky P1-Val allowed peptide lifting and permitted catch bond 4 (Figure S7) . Second, P6 in Pep20 and HIV formed a salt bridge with Arg97 on the b sheet floor of B35. As TCR55 was sheared, the P6-mediated salt bridge anchored the central residues while the N terminus of the peptide lifted. For Pep20, this bond length remained $12.3 Å , acting as a stiff spring ( Figure S7 ). However, during the shearing process, the bond ruptured and allowed for CDR3b-Arg96 to orient to support catch bond formation (Figures 7B and S7; catch bond 3) . For HIV, the extra methylene group in P6-Glu reduced the strength of the anchoring bond and sterically prevented catch bond 3 formation. The MD simulations highlight how subtle changes to the TCR-pMHC interface can lead to dramatic differences in signaling outcomes.
DISCUSSION
We have taken an unconventional approach to dissecting TCRtriggering mechanisms by studying TCRs that engage pMHC ligands but do not initiate productive signaling. We hypothesized that a systematic, detailed comparison of signaling versus nonsignaling pMHCs could allow us to isolate a molecular basis for this discordance. We used a pMHC library to isolate peptides in which signaling outcome was altered by minimal changes in peptide sequence that, crucially, did not significantly alter binding affinity. Our study isolates catch bond formation and CD45 exclusion as principal emergent properties differentiating stimulatory from non-stimulatory TCR-pMHC interactions. Perturbations of TCR-pMHC interface chemistry as a result of peptide substitutions, alterations in docking geometry, or TCR CDR mutations can dramatically impact the coupling of binding to signaling (Adams et al., 2011; Baker et al., 2000; Degano et al., 2000; Kalergis et al., 2001) . Catch bond formation, the origins of which are rooted in the structural chemistry and energetic landscape of the TCR-pMHC interface, appears to be deterministic for productive signaling upon TCR-pMHC engagement and likely explains anomalous relationships between TCR-pMHC binding strength and signaling. Catch bonds may play a role in explaining alloreactivity to MHC molecules with minor polymorphisms (Luz et al., 2002) .
Reconciling Intrinsic and Extrinsic Models of TCR Triggering
APLs are often designed to abrogate TCR binding, limiting the ability to probe the biophysical basis of TCR signaling (Aleksic al., 2010; Ding et al., 1999; Evavold and Allen, 1991; Holler and Kranz, 2003; Johanns et al., 2010; Sloan-Lancaster and Allen, 1996) . Numerous studies have argued that parameters intrinsic to the TCR can account for T cell signaling potency. These include (1) affinity, kinetics, 2D confinement time, and 2D on-rate (Aleksic et al., 2010; Huang et al., 2010; Huppa et al., 2010) and (2) structural influences such as conformational change, docking geometry, and complex stability (Adams et al., 2011; Beddoe et al., 2009; Das et al., 2015; Kim et al., 2009; Krogsgaard et al., 2003; Minguet et al., 2007; Natarajan et al., 2017) . Our initial efforts focused on a systematic comparison of intrinsic TCR-pMHC parameters between functionally disparate interactions. We measured 2D binding using two different methods. By TIRF microscopy, TCR589 and TCR55 exhibited similar dwell times to B35-HIV (Pol [448] [449] [450] [451] [452] [453] [454] [455] [456] ). However, by 2D micropipette, TCR589 showed a higher 2D affinity compared to TCR55. It is possible that an additional class of faster interactions exist that could not be resolved from stochastic events and therefore were unmeasured by TIRF microscopy. Furthermore, crystal structures of these TCR/pMHC complexes showed that the non-agonist interactions bound with similar docking geometries to the agonist complexes, thus ruling out TCR-pMHC topology alone as the explanation for signaling differences, consistent with studies in other systems (Ding et al., 1999) . Prior studies have also shown permissiveness in docking topologies compatible with signaling (Beringer et al., 2015) . Nevertheless, since TCR-pMHC docking geometry determines the interface chemistry, which in turn determines whether a given interaction will form catch or slip bonds, these structural parameters are linked, providing a mechanism for how TCR-pMHC topology could influence signaling outcome (Adams et al., 2011) .
A challenge to ''intrinsic'' models of TCR triggering is that T cells can be triggered independently of TCR-pMHC binding, solely by exclusion of the phosphatase CD45 (Chang et al., 2016; Davis and van der Merwe, 2006) . The kinetic segregation model, which we refer to as an ''extrinsic'' model, postulates that the exclusion of CD45 from the region of the TCR-pMHC interaction promotes a shift in the equilibrium between the co-receptor-bound kinase LCK and phosphatase CD45, favoring the phosphorylated state of the ITAMs of the TCR. Additionally, studies using anti-CD3 antibodies under varying amounts of force (Hu and Butte, 2016) and immobilized on materials with differential stiffness properties (Judokusumo et al., 2012; Saitakis et al., 2017) have tuned signaling potency based on mechanical force alone.
Our data are consistent with a model that reconciles intrinsic and extrinsic models of TCR triggering: TCR-pMHC interactions at the membrane interface are prolonged by the formation of catch bonds, allowing for prolonged local CD45 segregation and potentiating subsequent downstream activation. Alternatively, catch bond formation could cause a peptide-specific increase in TCR-pMHC dwell time in areas from which CD45 is segregated ( Figure S6 ). The presumed low number of agonist pMHC supports the latter. Importantly, it has been suggested that thermal fluctuations in membrane shape can lead to substantial changes in force on a given TCR-pMHC interaction (Pullen and Abel, 2017; Schmid et al., 2016) . This could contribute to a sharp threshold for ligand discrimination by disrupting weak, non-agonist, TCR-pMHC interactions or, in the case of agonists, promote catch bond formation leading to a peptide-specific increase in TCR-MHC dwell time. Catch bonds, also termed flex bonds, can compensate for the apparently fast 3D k off , characteristic of many physiological interactions between adhesive proteins and thus contribute to a higher probability in receptor signaling (Kim et al., 2010; Liu et al., 2014; Luca et al., 2017) .
Molecular Dynamics Modeling of Catch Bond Formation
Extension of bond lifetime under force has been experimentally shown for TCR-pMHC interactions, but the details of this process are poorly understood (Hong et al., 2015; Liu et al., 2014) . The TCR-pMHC catch bond formation mechanism, as elucidated by MD simulations, differs from other receptorligand catch bond interactions in that there was no apparent gross conformational change at the interface (Lou and Zhu, 2007; Manibog et al., 2014; Sauer et al., 2016) . We reveal a dynamic mechanism for TCR specificity and cross-reactivity that is rooted in the structure of the TCR-pMHC interface and illustrate how TCRs can be sensitive to minimal changes in the peptide. The simulations also highlight a surprising finding: peptide residues buried in the MHC groove can play an important role in modulating T cell activation by acting as molecular springs that modulate catch bond behavior (Ding et al., 1999) . Interestingly, the same pMHC can be an agonist or non-agonist for different TCRs, although it is difficult to assign causality to either the TCR or the peptide-MHC. The formation of a catch or slip bond is a collective property of the entire TCR-pMHC interface (Evavold and Allen, 1991; Hawse et al., 2014) .
Role of Non-agonist Interactions In Vivo
Classically, T cell clones specific for a pMHC have been identified by activation assays. By circumventing the requirement for activation using tetramer selections, we isolated TCRs that bind to a ligand but do not activate T cell signaling. Single-cell tetramer sorting assays have previously observed a number of similar non-agonist TCR-pMHC interactions in vivo (Moon et al., 2007; Yu et al., 2015) . These non-responsive T cell clones were previously thought to be a consequence of anergic or senescent T cells but may in fact be inherent to the molecular interaction between the pMHC and the TCR. Tetramer sorting may not identify functionally relevant T cell clones, as some fraction of these are likely non-agonist interactions (Martinez et al., 2016; Moon et al., 2007) .
Peptide antigens that give rise to non-stimulatory TCR interactions could be conceivably exploited as a strategy for immune evasion by viruses (Ploegh, 1998) or even by neoantigens in cancer to escape killing by tumor infiltrating lymphocytes. Many of the previously reported non-agonist interactions were observed for viral antigens, including HIV, hepatitis-C virus, and Epstein-Barr virus. Conservative mutations may allow viruses to manipulate TCR recognition and blunt a particular clonal T cell response, implying a functional selection of viral mutations to increase fitness. The observation that TCR binding can be uncoupled from signaling also suggests new strategies for immunotherapy engineering: identification of non-agonists for potentially pathogenic T cell clones in the context of autoimmune disease could be a novel approach to treatment. It may also be possible to enhance the potency of TCRs to self-antigens in the context of adoptive cell therapy through catch bond engineering rather than affinity maturation, which can lead to off-target toxicity (Linette et al., 2013) .
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Human Subjects
PBMCs were obtained from the Stanford Blood Bank. Cells in deidentified leukoreduction chambers from healthy platelet donors were processed as soon as possible and no later than 18 hr after plateletpheresis. For the isolation of T cell clones specific for HCV variants, PBMCs from 4 healthy male (ages: 53, 58, 40, 54) and 1 healthy female (age: 53) HLA-A*02+ donors were used. For isolation of HY specific T cell clones PBMCs from 3 healthy male donors (ages: 32, 28, 54) and 3 healthy female HLA-A*02+ (ages: 22, 21, 53) donors were used (Yu et al., 2015) . For isolation of DR4-HIV specific clones, PBMCs from 4 healthy HLA-DR4+ donors (3 M, 1 F ages 37-58) were used (Su et al., 2013.) Blood sample collection and processing was conducted in accordance with the rules and regulations of the Stanford institutional review board.
Cell Lines
Cell lines were kept in a humidified incubator at 37 C with 5% CO 2 unless otherwise denoted. Primary human T cells were cultured in RPMI (ThermoFisher), 10% heat inactivated FCS, 2% heat inactivated human AB serum, 100 U/ml penicillin G, 100 ug/ml streptomycin, 2 mM glutamine. IL-2 (Peprotech) was added to a final concentration of 100 U/ml. Primary T cell clones were isolated from donors mentioned in the human subjects section. Work done with blood samples was conducted in accordance with the rules and regulations of the Stanford institutional review board. SKW3 (derived from male with T cell leukemia), Jurkat b À/À (derived from a male with acute T cell leukemia) and 58 À/À (an XY murine T cell hybridoma derived from the BW5147 murine thymoma). T cell lines were cultured in RPMI + glutamax (Invitrogen) supplemented with 10% FBS supplemented with 5 mM HEPES pH 8.0 (ThermoFisher), and 50 U/ml penicillin and streptomycin (ThermoFisher). KG-1 cells are HLA-B35*01 expressing cells derived from a male with acute myelogenous leukemia. KG-1 cells were used as antigen presenting cells and were cultured in IMDM (ThermoFisher) + 10% FBS and 50 U/ml penicillin and streptomycin (ThermoFisher). SKW3 were purchased from DSMZ and KG-1 cells were purchased from ATCC. 58 À/À and Jurkat b À/À cells were a gift from Mark Davis (Stanford). Validation of T cell lines was performed by staining with known markers pre-and post-transfection. HEK293T Phoenix cells (female derived kidney cell line) were grown in DMEM complete media (ThermoFisher) supplemented with 10% FBS, 2mM L-glutamine, and 50 U/ml of penicillin and streptomycin.
The JY cell line is a male derived EBV-immortalized B cell line cultured in RPMI complete containing 10% FBS, 2 mM glutamine, and 50 U/mL penicillin and streptomycin. EBY100 yeast cells were grown in sterile filtered YPD Media containing 5 g yeast extract, 10 g peptone, and 10 g dextrose in deionized water. Transformed yeast were grown in SDCAA containing 20 g dextrose, 6.7 g Difco yeast nitrogen base, 5 g Bacto casamino acids, 14.7 g sodium citrate, and 4.29 g of citric acid monohydrate per liter of media, or SGCAA where Galactose replaces dextrose. EBY100 cells are grown at 30 C when cultured in SDCAA, or at 20 C when cultured in SGCAA at atmospheric CO 2 . High Five cells were grown in Insect X-press media (Lonza) with final concentration 10 mg/L of gentamicin sulfate (ThermoFisher) at 27 C at atmospheric CO 2 . SF9 cells are grown in SF900-III serum-free media (ThermoFishser) with 10% FBS and final concentration 10 mg/L of gentamicin sulfate at 27 C at atmospheric CO 2 . BL21 DE3 cells were cultured at 37 C at atmospheric CO 2 in Terrific Broth Media (Research Products International), supplemented with 6 mls of glycerol per 1.5 L of media. 1 mM IPTG was added in order to induce expression of the protein of interest.
DH5a were cultured in LB (Sigma) supplemented with either 100 ug/ml carbenicillin or 50 ug/ml of kanamycin. The cell lines were validated by staining for known cell surface markers. The parental SKW3, 58 À/À , and Jurkat b À/À cell lines do not have surface expressed TCR and were validated by surface staining with anti-TCR antibody (clone IP26) or tetramers. After transduction, TCR expression was confirmed by staining with specific fluorescent pMHC tetramers and anti-TCR antibodies. Bacterial, insect, and Phoenix 293 cells were not validated by cell surface marker staining, but were monitored daily for morphological integrity under brightfield microscopy.
METHODS DETAILS
Tetramer enrichment and T cell cloning LRS chambers containing PBMCs (Stanford Blood Center) from platelet donors were processed within 24 hr. T cells were concentrated by negative depletion with RosetteSep (StemCell Technologies). Red blood cells (RBCs) were lysed with ACK buffer, filtered through 70 mm mesh, and resuspended in flow cytometry buffer (PBS with 2% FCS, 0.5 mM EDTA) at 5 3 10 6 / ml. Cells were incubated 1 hr at room temperature in 20 nM pMHC tetramers (PE or PE-Cy conjugate), anti-CD8 antibody (Biolegend), anti-CD32 (BD Biosciences), anti-CD16 (Biolegend), and 50 mM biotin. After washing, cells were incubated with anti-PE Microbeads (Miltenyi) and tetramer enriched using LS columns (Miltenyi). After enrichment, the column fraction and an aliquot of the flow through were stained for 30 min on ice with a viability stain (either propidium iodide or Aqua Live/Dead Stain (Invitrogen)) and an additional antibody mixture either with anti-CD4 and anti-CD8. Tetramer enriched cells were single cell sorted into a round bottom 96-well plate containing 100 ml media (RPMI, 10% heat inactivated FCS, 2% heat inactivated human AB serum, 100 U/ml penicillin G, 100 ug/ml streptomycin, 2 mM glutamine) with a BD Aria cell sorter. Feeder cells were prepared from PBMCs from 2-3 random HLA buffy coats irradiated with 4000 rads in a cesium-137 irradiator. JY cells (Sigma-Aldrich) were irradiated with 12000 rads. 100 ml containing 75,000 PBMCs, 7,500 JY cells, and 160,000 anti-CD3/anti-CD28 beads (Dynal/Invitrogen) were added to each well after sorting. IL-2 (Peprotech) was added to a final concentration of 100 U/ml. Cells were kept in a humidified incubator at 37 C with 5% CO2. IL-2 and media were changed as needed, and the cells were reanalyzed for tetramer staining by flow cytometry. Re-stimulation of T cell clones was performed with PHA (GIBCO), IL-2 (100 U/ml), and irradiated mixed PBMCs and JY cells at 750,000 cells/ml and 75,000 cells/ml, respectively.
Primary T cell signaling
Cell proliferation was performed by labeling cells with 5 mM CFSE (Invitrogen) for 5 minutes at room temperature and co-cultured for 4-5 days with peptides (10 mg/ml) pulsed on peripheral monocyte derived dendritic cells, or non-specific stimuli (PHA or anti-CD3/ CD28 beads). Plates were spun down at 500 g and washed once with 1x PBS+0.1%BSA, and 0.5 mM EDTA. Cells were stained with tetramers, anti-CD16 (Biolegend), and anti-CD32 (BD Biosciences) for 1 hour at room temperature, followed by staining with the following antibody cocktail for another 10 minutes: anti-CD11b (Biolegend), anti-CD19 (Biolegend), anti CD4 (Biolegend), and anti-CD8 (Biolegend). Assay was read via flow cytometry. For cytokine analysis, T cell clones were stimulated with peptide pulsed on PBMCs obtained from the Stanford Blood Center for 10-12 hours at 37 C in the presence of protein transport inhibitor (GolgiStop, GolgiPlug, BD). Plates were spun down at 1500 rpm and assayed for intracellular cytokine production by staining cells with anti-IL-2 (Biolegend) and anti-IFN-g (eBiosciences) and co-stained with the antibody cocktail mixture described above.
CD107 mobilization assay was performed as described in (Yu et al., 2015) . Briefly, T cell clones were cultured with peptide pulsed T2 (HLA A*02+ APC; ATCC) cells in a 1:1 ratio. 50,000-100,000 of each cell type were mixed in 50 mL of media in the presence of CD107a antibody (BD Biosciences), peptide, 10 mM monensin. The plate was centrifuged at 300 g for 1 minute to pellet cells and the plate was placed into an incubator at 37 C for 4.5 hours. After incubation the plate was spun at 500 g to pellet cells and remove supernatant. Cells were washed once with 1x PBS+0.1%BSA, and 0.5 mM EDTA. Cells were stained with tetramers and/or CD3 (BD Biosciences) and CD8 (Biolegend).
Retroviral transduction of TCRs
TCR a and b chains were cloned separately into retroviral pMSCV vectors. Plasmid DNA sequence integrity were verified by automated fluorescent dideoxy (Sanger) sequencing (Sequetech). 1 3 10 6 Phoenix (293) cells were plated in 3.5 mls of DMEM complete media (10% FBS, 10 mM HEPES, Pen-strep, L-glutamate) in a 6-well plate. In a cryo-vial (Fisher). 182 mL of unsupplemented DMEM (Thermo Fisher) was mixed with 18 mL of FuGENE (Promega) was incubated at room temperature for 5 minutes. 5.5 mg of DNA from either TCRa, TCRb, or CD3 vectors was mixed with 1.1 mg of pCL-10A (Novus Biolgicals) and added to DMEM-FuGENE mixture and left to incubate for 30 minutes at room temperature. Transfection mixtures for TCRa, TCRb, or CD3 encoding plasmids were added to separate wells of Phoenix cells and left overnight at 37 C. Media was changed the following day and transferred to a 32 C incubator. The next morning, supernatants were harvested and collected, and replaced with fresh complete DMEM. Supernatant was kept at 4 C. The next day supernatants were harvested, collected and combined (TCRa, TCRb, and CD3). Supernatants containing virus were filtered through an 0.45 mm filter and concentrated using a 100 kDa spin filter (Amicon) until the total volume reached 0.5-1 ml. Concentrated virus was buffer exchanged into RPMI complete using 100 kDA filter and again concentrated to 0.5 -1 ml. Concentrated virus was added to 2 3 10 6 either SKW3, 58
, Jurkat b À/À cells in 12 well plates. Plates containing cells and virus were spun at 2500 rpm for 2 hr at 32 C. After centrifugation plates were returned to 37 C incubator. TCR expression was checked by antibody and tetramer staining via flow cytometry after 5 days. TCR+ CD3+ population was sorted for further use.
IL-2 ELISA 58
À/À transduced T cells were rested overnight in RPMI complete. KG-1 antigen presenting cells (APCs) were pulled with desired concentration of peptide for 2 hours or overnight at 37 C. For stimulation of TCR6 and TCR11 58 À/À transduced T cells, plates
were coated with desired concentration of recombinant DR4-HIV(Gag) monomer at 4 C overnight. APCs were washed once to remove excess peptide. T cells and APCs were mixed at a ratio of 1:1 and incubated at 37 C for 24 hr. Secreted IL-2 was measured using the Ready-Set-Go mouse IL-2 Elisa Kit (EBiosciences) as recommended by the manufacturer. Briefly, 96-well flat bottom plates (Corning Costar; 9018) were coated with 100 mL of capture antibody diluted in supplied 1x coating buffer, sealed, and set at 4 C overnight. Wells were aspirated and washed three times with 200 mL of PBST (1x PBS + 0.05% Tween À20). Plates were then blocked with 200 mL of 1x ELISA/ELISASPOT diluent and incubated at RT for 1 hour. The plate was washed 1x with PBST. 100 mL of sample was added to desired wells as well as a standard curve of IL-2 (prepared as recommended by eBioscience). Plates were sealed and incubated for 3 hours at room temperature shaking at 200 rpm. The samples were pipetted off and the plates were washed 5 times with 200 mL of 1xPBST. 100 mL of diluted detection antibody was added to each well and plates were incubated for 1 hour. Samples were pipetted off and the plates were washed 5 times with 1xPBST. 100 mL of diluted Avidin-HRP was added to each well, and the plate was incubated at room temperature for 30 minutes. The plate was washed 7 times with 1xPBST. 100 mL of 1xTMB solution was added to the plates. Plates were incubated for 15 minutes at room temperature. Reaction was quenched with 100 mL of 1 M H 3 PO 4 and the plate was read at 450 nm and 570 nm on Spectra Max Paradigm (Molecular Devices). Antibodies were diluted in 1x diluent as recommended by specific kit. Assay was performed in biological and technical triplicates.
CD69 upregulation SKW-3 T cells were rested overnight or for 2-3 hours in fresh RPMI complete. KG-1 antigen presenting cells were pulsed with desired concentration of peptide for 2-3 hours incubated at 37 C. KG-1 cells were washed to remove excess peptide and re-suspended with rested SKW3 T cells. Cells were co-cultured for 14 hours. Cells were stained with anti-CD3 (UCHT-1, BD Biosciences) (1:100) and anti-hCD69 (1:100) (Biolegend) for 1 hour on ice in PBSA (PBS+0.5% BSA). Cells were washed once and analyzed via flow cytometry on an Accuri (BD Biosciences) or Cytoflex (Beckman Coulter). Assay was performed in biological and technical triplicates. EC 50 was determined in Prism.
Phospho-Flow Cytometry SKW-3 T cells were rested overnight in RPMI complete. KG-1 antigen presenting cells were pulsed with desired concentration of peptide for 2-3 hours. KG-1 cells were washed and re-suspended with SKW cells. Cells were mixed 1:1 with 125,000 cells of each cell line per well. Cells were co-cultured for 15 minutes at 37 C. Cells were immediately fixed with 4% PFA (Sigma) and centrifuged at 1500 rpm for 5 minutes. Cells were re-suspended in 100 mL of Cytofix (BD 554655) and were left at 37 C for 30 minutes. Cells were washed with PBS+2% FBS, and permablized in ice cold methanol or Perm Buffer III (BD) on ice for 30 minutes. Cells were transferred to deep well blocks, and were washed 3 times with PBS+2% FBS. Samples were stained with a 1:50 dilution of anti-pERK1/2 (Cell Signaling #13148s), and 1:100 of Anti-CD3 (UCHT-1-APC, BD Biosciences) for 1 hour at room temperature shaking. Cells were washed once and analyzed via flow cytometry on an BD Accuri or Cytoflex. Assay was performed in biological and technical triplicates.
Calcium Imaging 100 ml of 1 mM pMHC, 100 ml of 1 ug/ml anti-CD3 (clone OKT3), or 100 ml of 10 mg/ml bovine IgG in 1x HBS were plated on FluoroDish (World Precision Instruments FD3510-100) in 1 x HBS overnight at 4 C . Fluo-4 was dissolved in DMSO to 4 mM and divided into 0.5 mL aliquots. On day of imaging, T cells were rested for 2 hours in fresh RPMI complete. Just before imaging, 1 x 10 6 cells were centrifuged at 2000 rpm for 90 s and re-suspended in 200 mL of HBS pH 7.2. 200 mL of 2.5 mM probenecid (dissolved in HBS) was added to one 0.5 mL aliquot of 4 mM Fluo-4. Cells were mixed with the Fluo-4-probenecid solution and 200 mL of RPMI (non-supplemented). Cells were incubated in the dark for 20-30 minutes at room temperature. Cells were centrifuged at 2000 rpm for 90 s and re-suspended in 200 mL of 2.5 mM probenecid/HBS. FluoroDishes containing ligand were washed once with 250 mL of 1 x HBS. 100 mL of cells were pipetted on the Fluorodish and imaged at 488 nm excitation with a frame rate of 500 ms. Movies were taken with a Zeiss Axio Observer 7 and Photometrics Prime camera. Assay was performed in biological triplicates. Movies were analyzed using a modified version of Calquo (https://www.nano-immunology.org/software.html) to detect single-cell landing events on the prepared coverslip surfaces, and to record fluorescence intensities over time at the coverslip surface. Briefly, for each cell, stable changes in fluorescence intensity above background levels were indicative of the cell 'landing' and calcium responses associated with SKW T cell signaling (> 1.5 fold fluorescence intensity above 'landing' intensity). For each cell, the time lapse between 'landing' and 'signaling' was also determined. All cells were individually analyzed and the fraction of signaling cells was determined from the total number of cells detected after landing, provided that cells landed before frame 480, in order to allow 3 minutes for signaling to occur.
Electroformation of GUVs
Lipids were mixed in chloroform (Electron Microscopy Sciences, 12550) in a glass vials (Thermo Scientific, C4010-1, C4010-60A) using Hamilton syringes (Hamilton, 1701 (Hamilton, , 1705 (Hamilton, , 1710 . Separate syringes were used for fluorescent and non-fluorescent lipids. The total lipid concentration should be between 2 mg/ml and 10 mg/ml. For this study, GUV composition was 94.9% POPC (Avanti, 850457), 5% DGS-NTA (Avanti, 790404), 0.1% Atto 390-DOPE (AttoTec, AD390-161) (total [lipid] $3mM). An Ohmmeter (Neoteck, NT8233D) was used to identify the conductive side of the ITO-coated slide (Sigma Aldrich, 636908). Using a Hamilton syringe, 10 ml of lipid solution was spread in each of three spots on the conductive surface of a slide that was kept warm on 37 C heat block. The lipid containing ITO-coated slide was immediately placed into a vacuum desiccator (Thermo Scientific, 53110250) and allowed to dry for at least 1 hour.
U-shaped Silicone gaskets cut from silicone sheet, (McMaster-Carr, 9010K12) were cleaned with soap and water then rinsed with acetone and ddH2O, and dried with a Kimwipe. The gaskets were pressed onto to the conductive side of the ITO-coated slide, directly around the dried lipid films. Conductive copper tape (StewMac, 0036) was affixed to the conductive side of ITO-coated slide with the gaskets and dried lipid film and to a second ITO-coated slide, at the corners. The second ITO-coated slide was pressed on top of the gaskets, with the conductive surface facing the gaskets, so that the two ITO-coated slides form a capacitor-like configuration. Two binder clips were used to fix the slide chamber. The gaskets were then filled with appropriate volume of 370 mM sucrose solution ($200 uL). The chambers were then carefully sealed using modeling clay (Sculpey, 301209), while avoiding introducing bubbles.
The ITO-coated slides were connected to a function generator (B&K Precision, 4012A) via wires with alligator clips and the copper tapes. The chamber was then placed into a 60 C oven. An alternating voltage (1-4 V, 10 Hz) was applied for 3 hours, during which GUVs formed within the slide chamber. The optimal voltage for forming GUVs was empirically determined. Greater than 5V voltage should not be used as it could damage the ITO slides.
After the 3-hour formation, the GUV chamber was removed from the oven, and carefully disassembled. The modeling clay was removed and GUV solution was withdrawn using a P200 pipette with a blunt tip. GUVs were stored at room temperature and imaged within one week. For more information see (Schmid et al., 2016) .
Reconstitution of membrane interfaces
Prior to protein functionalization, SLBs were incubated with 0.6 mg/mL Cy2-Streptavidin (Jackson ImmunoResearch, 016-220-084) for 10 minutes then washed 6 times with ½ total well volume of phosphate buffered saline pH 7.4. GUVs and SLBs were then separately incubated for one hour. CD45 R ABC was added to GUVs at a final concentration of 20 nM, and TCR55 was added to GUVs at a final concentration of 5 nM. The indicated pMHC (HIV, Pep20, SQL,) was added to the supported lipid bilayer at a final concentration of 10 nM. Proteins were diluted in reaction buffer (50 mM HEPES, 150 mM NaCl, 1 mM TCEP, 1 mg/mL bovine serum albumen, pH 7.4) and then mixed 2:1 with GUVs, or added to supported lipid bilayers. SLBs were washed 6 times with ½ total well volume resulting in a final concentration of $1% input protein remaining. The GUVs were not washed but were diluted 10-fold into the imaging well with the supported lipid bilayer after a 1 hour incubation. GUVs were allowed to settle for 30-60 min prior to imaging. SLB fluidity was assessed by visualizing diffusion of unbound GUV proteins that associate with the supported lipid bilayer (e.g., TCR, CD45). If > 25% of fluorescent molecules on the SLB were not diffusive, the experiment was repeated with a more fluid bilayer.
Preparation of SLBs for Zap70 imaging
Small unilamellar vesicles (SUVs) were prepared from a mixture of 97.3% POPC (Avanti), 2% DGS-NGA-Ni (Avanti), 0.5% PEG5000-PE (Avanti), and 0.2% Biotinyl Cap PE (Avanti). The lipid mixture in chloroform was evaporated under argon and further dried under vacuum. The mixture was then rehydrated with phosphate buffered saline pH 7.4 and cycled between À80
C and 37 C 20 times, and then centrifuged for 45 min at 35,000 RCF. SUVs made by this method were stored at 4 C and used within two weeks of formation. Supported lipid bilayers were formed in freshly plasma cleaned custom PDMS chambers on RCA cleaned glass coverslips. 100 mL of SUV solution containing 0.5 to 1 mg/ml lipid was added to the coverslips and incubated for 30 min. Unadsorbed vesicles were removed and bilayers were blocked by washing three times with reaction buffer (50 mM HEPES, 150 mM NaCl, 1 mM TCEP, 1 mg/mL bovine serum albumen, pH 7.4), and incubating for 20 min. Percent of cells that clustered was calculated by manual scoring of cells that were randomly selected, the error reported is the standard deviation for 2 pooled biological duplicates. Total number of cells reported in figure legend.
TIRF microscopy setup for Zap70 imaging
Imaging was performed on a Nikon TI-E microscope equipped with a Nikon 100x Plan Apo 1.49 NA oil immersion objective, and four laser lines (405, 488, 561, 640 nm), a Hamamatsu Flash 4.0 and mManager software (https://micro-manager.org/). A polarizing filter was placed in the excitation laser path to polarize the light perpendicular to the plane of incidence. Angle of illumination was controlled with a Nikon TIRF motorized positioner.
Dwell time imaging chamber and SLBs
Single unilamellar vesicles (SUVs) were formed by tip sonication of a solution composed of 98 mol % 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 2 mol % 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel salt) (Ni2+-NTA-DOGS) (Avanti) in Mill-Q water (EMD Millipore). Prior to experiments, No. 1.5 round coverslips with 25 mm diameter were ultrasonicated for 30 min in 50:50 isopropyl alcohol:water, rinsed thoroughly in Milli-Q water (EMD Millipore), etched for 5 min in piranha solution (3:1 sulfuric acid:hydrogen peroxide), and again rinsed thoroughly in Milli-Q water. The coverslips were used in the assembly of Attofluor chambers. SUVs were then deposited onto the coverslip with a 1:1 mixture of 1 mg/mL lipids and 1x Tris-buffered saline (TBS; 19.98 mM Tris, 136 mM NaCl, pH 7.4; Mediatech Inc.,). Bilayers were allowed to form for at least 30 min. The bilayers were rinsed with TBS, incubated for 5 min with 100 mM NiCl2 in TBS, rinsed with TBS, and then rinsed with a T cell imaging buffer composed of 1 mM CaCl2, 2 mM MgCl2, 20 mM HEPES, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 6 mM d-glucose, and 1% w/vol bovine serum albumin. The Atto647-B35-HIV(Pol)-His10 protein described below was incubated with the functionalized SLB for 35 min followed by rinsing with imaging buffer. T cells were re-suspended in imaging buffer and added to the Attofluor chamber and were imaged immediately, with ongoing data collection up to 30 min. All other incubations during this protocol were performed at room temperature, and imaging experiments were performed at 37 C.
Dwell time measurements via TIRF TIRF dwell time experiments were performed on an inverted microscope (Nikon Eclipse Ti; Technical Instruments) using a custombuilt laser launch with 488 nm (Sapphire HP) and 640 nm (Cube; Coherent Inc.) diode lasers, as described previously (O'Donoghue et al., 2013). Laser power was measured at the sample at 0.7 mW (640 nm) for the 400 ms exposure. Fluorescent images were recorded using an EM-CCD (iXon 597DU; Andor Inc., South Windsor, CT). ET660LP and ET700/75M filters were used for 647 nm channel imaging. Exposure times and time-lapse periods were set using image collection software (Micro-Manager 1.4.19), which drives an Andor iXon Ultra camera. Single particle tracking of B35-HIV-10xHis-195c-647N or B35-Pep20-10xHis-195c-647N was done with the TrackMate plugin for ImageJ from raw tif image stacks. Size, intensity, and mobility thresholds were first determined by eye to filter out spurious detections or immobile defects and then applied uniformly to all data collected with the same imaging conditions. The dwell time distributions are roughly exponential, with the bleaching rate being approximately 20 times slower than the observed dwell events. Further plotting and analysis were done with in-house developed Python scripts.
UV mediated peptide exchange UV-sensitive pMHC monomer was produced by refolding (as described below) HLA-B35 with a synthesized (Stanford Pan Facility) UV cleavable peptide VPLRPM'J'Y (here J represents Fmoc-(S)-3-amino-3-(2-nitrophenyl)propionic acid (ChemImpex, 15606). In a 96-well plate 10x UV-sensitive MHC monomer (12.5 mL of 5 mM), 10x desired exchange peptide (12.5 mL of 500 uM) were added to 100 mL of 20 mM Tris-HCl pH 7.0, 150 mM NaCl. The plate was placed on ice and put under a UV lamp for 1 hr; distance of the UV lamp to the sample was 2-5 cm. The plate was then centrifuged for 5 min at 3300 g at room temperature 80 mL of supernatant was transferred into tubes. Exchanged pMHC was either stored at 4 C for 1 week and used or stored at À20 C in 20% glycerol.
Surface plasmon resonance
Affinity measurements for TCR589 and TCR55 bound to peptides presented by HLA-B35 were determined by surface plasmon resonance on a Biacore T100 (GE Healthcare). For measurements of TCRs binding to HLA-B35-HIV(Pol 448 -456 ), the pMHC was refolded and biotinylated as described above and the TCRs were expressed using baculovirus or refolded. If expressed using baculovirus, the TCRs were incubated with 3C protease in order to cleave off acidic and basic zippers before purification. For measurements of library derived peptides, HLA B35 was refolded with a UV cleavable peptide VPLRPM'J'Y (here J represents Fmoc-(S)-3-amino-3-(2-nitrophenyl)propionic acid). UV mediated peptide exchange was performed as described above. 100-300 RU of pMHC exchanged with the peptide of interest were immobilized to a Biacore Series S SA Chip (GE healthcare). H2 K b -VSV was used as the reference surface. SPR runs were performed in HBS-P+ (GE Healthcare) + 0.1% BSA. All measurements were made with 2 or 3 fold serial dilutions of TCR using 60 s association followed by 180 s dissociation at 10-30ul/min flow rate at 25 C. No regeneration of the surface was required because the samples completely returned to baseline during dissociation. Measurement of titrations at equilibrium were used to determine the K D using Biacore Analysis Software (GE Healthcare).
BFP assay
Bond lifetime measurements under force were captured using the Biomembrane Force Probe Assay (BFP). Procedures for coupling pMHC to glass beads have been described (Liu et al., 2014) . In brief, RBCs were first biotinylated with EZ-link NHS-PEG-Biotin (Thermo Fisher Scientific) and then reacted to streptavidin; borosilicate beads were first cleaned, silanized, and then reacted to streptavidin-maleimide (Sigma-Aldrich). Streptavidinized beads were then coated with cognate pMHC (HLA B35-HIV(Pol 448-456 ) or with B35-Pep20 or B35-SQL and then to a RBC that is aspirated onto a micropipette. This bead serves as a force probe, the position of the edge of the bead can be tracked by the high-resolution camera (1,600 frames/sec) with < 3 nm displacement precision. The T cell of interest is brought into contact with the glass bead and then retracted a set distance and held by the computercontrolled piezoelectric actuator. The retraction and hold phase generates a force on the TCR:MHC bond, which can be altered, based on the distance the T cell is retracted. The camera then records the time it takes for the T cell to disengage the glass bead, which can visually be seen by the RBC retracting and the bead returning to its starting position. Multiple repeated cycles (known as force-clamp cycles) can be carried at a single force in order to generate an average bond lifetime between the TCR and peptide:MHC complex. By varying the force and measuring the bond lifetimes one determines what type of bond occurs. For optimal response to antigen the bond lifetimes increase with increasing force before reaching a peak bond lifetime, which is typical of a catch bond physiology. Alternatively, many protein:protein interactions show shorter bond lifetimes as force is applied to the bond (called a slip bond).
2D affinity measurements by micropipette adhesion frequency assay
The micropipette adhesion frequency assay was employed as previously described (Huang et al., 2010; Martinez et al., 2016) . In brief, human RBCs were isolated in accordance with the Institutional Review Board approval. RBCs were coated with Biotin-X-NHS (EMD Millipore) streptavidin (Thermo Fisher Scientific) and then coated with pMHC HLA B35-HIV(Pol 448-456 ) or with B35-Pep20 or B35-SQL. pMHC coated RBC's and TCR589 or TCR55 CD8 deficient T cells were aspirated onto apposing pipettes and brought into contact 50 times with the same and area (A c ) and time. An electronically controlled piezoelectric actuator repeated T cell contact with the pMHC coated RBC's. Upon retraction of the T cell, adhesion (binding of TCR-pMHC) was observed by distention of the RBC membrane, allowing for quantification of adhesion frequency (P a ) at equilibrium. Surface pMHC (m l ) and TCRbeta (m r ) densities were determined by flow cytometry and BD QuantiBRITE PE Beads for standardization (BD Biosciences). The relative 2D affinities were calculated using the following equation: A c K a = -ln [1-P a (1)]/m r m l . Geometric mean affinities are reported ± SEM.
Protein Production and Purification
Baculovirus production of TCRs a and b chains of TCRs were cloned separately into the pAcGP67a vector (BD Biosciences). Each of the chains used the polyhedrin promoter to express the TCR V region with human constant domains truncated at the connecting peptide, with an engineered cysteine to promote alpha and beta chain pairing. The alpha and beta chains either expressed a C-terminal acidic GCN4 zipper À6x His tag or a C-terminal Basic GCN4 zipper -6xHis tag. Each chain contained a 3C protease site N-terminal to the zippers. Chains that contained the acidic zipper also had a biotinylation acceptor peptide (BAP) (GLNDIFEAQKIEWHE). DNA was co-transfected into 2 mL of SF9 cells at 1 x 10 6 cells/ml with linearized baculovirus vector (Baculogold, BD Biosciences) with Cellfectin II (Life Technologies). The virus (P0) was harvested and was amplified at a dilution of 1:1000 in 25 mL cultures at 1 3 10 6 cells/mL (P1 virus), 25 mls of supplemented SF900 was added 24 hours after addition of P0 virus. The P1 viruses of the TCR chains were then co-titrated in 2 mL of Hi5 cells at 2 3 10 6 cells/mL to optimize TCR alpha and beta chains for 1:1 expression. Optimal titrations were decided by analysis via SDS-PAGE gel and Coomassie staining. Co-titrations ranged from 1:1000 to 1:250 for each chain. P1 virus was used to infect volumes of 1 L (scaling up as necessary) of Hi5 cells at $2 x 10 6 cells/ml. Cells were removed 2-3 days post-infection and spun down at 2000 rpm for 10 minutes. The supernatant containing expressed protein was treated to 100 mM Tris pH 8.0, 1 mM NiCl 2 , and 5 mM CaCl 2 to precipitate contaminants. The supernatant and precipitate mixture was spun down at 6000 rpm for 15 min at room temperature to remove precipitate. The supernatant was incubated with Ni-NTA resin (QIAGEN) for $3 hours at room temperature. Ni-NTA beads were collected and washed in a buchner funnel with 20 mM imidazole in 1 x HBS pH 7.2 and then eluted with 200 mM imidazole in 1xHBS 7.2. Protein was concentrated in a 30 kDa filter (Milipore, UFC903024) to 500 ml-1 mL. If necessary, protein was biotinylated with BirA ligase, 100 mM biotin, 40 mM Bicine pH 8.3, 10 mM ATP, and 10 mM Magnesium Acetate at 4 C overnight. If necessary (for Biacore or crystallography) protein was treated with 3C protease overnight before purification via size-exclusion chromatography.
TCRs were purified by size-exclusion chromatography using an AKTAPurifier (GE Healthcare) using a Superdex 200 column (GE healthcare) in 1xHBS buffer pH 7.2. Fractions were collected at the proper size, and run on SDS-PAGE gel to confirm 1:1 stoichiometry and if necessary biotinylation or 3C cleavage. Fractions were pooled at TCRs were quantified by nanodrop and frozen at À80 C for storage.
Refolding of TCRs TCR a and b chains were cloned into the pET28a vector and separately expressed as inclusion bodies (IBs) in the E. coli strain BL21 DE3 (NEB). The cells were lysed in 50 mM Tris pH 8.0, 1% v/v Triton X-100, 1% w/v Na-Deoxycholic acid, 100 mM NaCl, 5 mM MgCl 2 , and 0.2 mM PMSF, and benzonase. Following lysis, lysates were sonicated and 10 mM Na-EDTA was added. The lysed mixture was spun down for 15 min at 10,000 G at 4 C to collect IBs. IBs were washed twice with 50 mM Tris pH 8.0, 0.5% Triton X-100, 100 mM NaCl, 1mM Na-EDTA, 1 mM DTT 0.2 mM PMSF and once in the same buffer omitting the Triton-X. IBs were solubilized in 20 mM Tris pH 8.0, 6 M urea, 0.5 mM EDTA, and 1 mM DTT. IBs were quantified and assessed for purity via SDS-PAGE, and run along side a BSA standard.
TCRs were refolded in 5 M urea, 100 mM TRIS pH 8.0, 2 mM Na-EDTA (pH 8.0) 400 mM L-Arginine-HCl (Sigma), 0.5 mM oxidized glutathione, 5.0 mM reduced glutathione, 0.2 mM PMSF at 4 C. 10 mgs of TCRa and 15 mgs of TCRb were injected into the cold stirring, refold buffer through a 27-gauge needle. This injection was repeated 2 additional times over every 12 hours. Refold mixture was transferred into dialysis tubing (8,000 MWCO), and was dialyzed against 10 mM TRIS pH 8.0 for 36-48 hours changing the buffer every 12 hours.
The TCRs were purified using ammonium sulfate precipitation. The refolding mixture was brought up to 30% ammonium sulfate and stirred at 4 C for $30 minutes. The mixture was spun down and the precipitate discarded. The refolding-ammonium sulfate mixture was then brought up to $60% ammonium sulfate and stirred at 4 C for 30 minutes. The mixture was then spun down at 10,000 g, the supernatant was discarded and the precipitate kept and dissolved in 1xHBS. The mixture was then dialyzed against 1xHBS overnight.
The TCR was then purified by size exchange chromatography in 10 mM Tris pH 8.0 as described above using an S200 column. Fractions were collected and analyzed by SDS-PAGE and Coomassie staining. If necessary fractions were concentrated and put over anion exchange column (MonoQ) to separate ab heterodimers from bb homodimers. The resulting protein was again run on an SDS-PAGE gel to assess purity. Fractions were collected at concentrated and buffer exchanged into 1 x HBS pH 7.2 and quantified and stored as above. pMHC Production HLA-B35*01 and hb2m were cloned into the pET28a vector and separately expressed as inclusion bodies (IBs) in the E. coli strain BL21. For single molecule imaging or tetramer production the construct included the following modifications: a mutation of to cysteine at position 195 to allow for single molecule labeling, the addition of a C-terminal His 10 for attachment to bilayers, or the addition of a C-terminal biotin acceptor peptide (BAP). The cells were lysed in 50 mM Tris pH 8.0, 1% v/v Triton X-100 (Sigma Aldrich), 1% w/v Na-Deoxycholic acid, 100 mM NaCl, 5 mM MgCl 2 , and 0.2 mM PMSF, and benzonase. Following lysis, IBs were sonicated 10 mM Na EDTA was added and spun down for 15 min at 10000 G at 4 C to collect IBs. IBs were washed twice with 50 mM Tris pH 8.0, 0.5% Triton X-100 (Sigma Aldrich), 100 mM NaCl, 1 mM Na-EDTA, 1 mM DTT, and 0.2 mM PMSF, and once in the same buffer omitting the Triton-X. IBs were solubilized in 20 mM Tris pH 8.0, 6 M urea, 0.5 mM EDTA, and 1 mM DTT. IBs were quantified and assessed for purity via SDS-PAGE, and run along side a BSA standard. B35*01 was refolded in 100 mM Tris (pH 8), 2 mM Na-EDTA, 400 mM L-arginine, 0.5 mM oxidized glutathione, 5.0 mM reduced glutathione, and 0.2 mM PMSF at 4 C. 500 ml of 20 mM peptide was added to the refolding mixture. A protease inhibitor tablet (Roche) was added to prevent degradation. Three injections of 15 mgs of B35 and 5 mgs of hb2m were added $12 hours to the refolding mixture for a total of 45 mgs of B35, and 15 mgs of hb2m. The refolding mixture was dialyzed against 20 mM Tris pH 8.0 for 36-48 hours changing buffer about ever 12 hours. The refolded material was filtered through a glass fiber filter and purified using weak anion exchange resin (DEAE Cellulose, Santa Cruz Biotechnologies) followed by purification via size exclusion chromatography (Superdex 200, GE Healthcare) and ion exchange (MonoQ 5/50, GE Healthcare). Anti-CD45 Fab production Mouse anti-human CD45 monoclonal antibody, clone Gap 8.3, was purified from supernatant of secreting hybridomas (ATCCâ HB-12). Cells were grown in DMEM supplemented with 10% FBS, Pen/Strep, 1x Sodium Pyruvate and 1x Glutamax. Gap8.3 was captured on immobilized protein A, eluted with 0.1 M Glycine, pH 3.0, immediately buffered with excess Tris-HCl pH 8.0, followed by gel filtration using on a Superdex Increase S200. mAb was fragmented using immobilized Papain (agarose resin; ThermoFisher Scientific), pre-activated with Cysteine-HCl at a final concentration of 20 mM, pH 7.0. Before digestion, Gap 8.3 was buffer exchanged to 20 mM Sodium Phosphate, 10 mM EDTA, pH 7.0. For the digestion, up to 10 mg of mAb in 1 ml, supplemented with 20 mM Cysteine-HCl, pH 7.0, were incubated with 1 mL of activated immobilized Papain bead slurry and left shaking at 37C for 16-18 hours. The Fc portion was separated from Fab by capture on immobilized protein A. All pre-and post-protein A purification samples were characterized by gel electrophoresis and the Fab containing samples were further purified by size exclusion using HBS buffer (10 mM HEPES, 150 mM NaCl). Fluorescent labeling of recombinant proteins B35 À195c was incubated with 10-fold molar excess of maleimide-Atto 647N (Atto-tec, cat # 647N-41; reconstituted to a 10 mM stock solution in DMSO) and TCEP (Sigma), for 2 hours at room temperature, protected from light. After incubation, 10-fold molar excess of Gluthatione, relative to protein molarity, (Sigma) was added and excess free dye was removed by gel filtration using a Superdex Increase S75 (GE).
For labeling protein with NHS chemistry, proteins of interest were incubated with a 10-fold molar excess of reconstituted Alexa Fluor NHS Ester (Thermo Fisher) for one hour at room temperature in the presence of 10 mM Sodium Bicarbonate, adjusted to pH 9.0. After incubation, excess free dye was removed by gel filtration using Superdex Increase S75 (GE).
Creation and selection of B35 yeast libraries
To obtain a functional HLA-B35 yeast display platform, error-prone evolution of a single-chain peptide-hb2m-HLA-B35 expressed on the surface of the S. cerevisiae strain EBY100 as an N-terminal fusion to Aga2 using the pYAL vector. The GenemorphII random mutagenesis kit (Agilent) was used to lightly mutagenize the region of the vector encoding HIV(pol)-hb2m-HLA-B35 (pYAL-B35(HIV)). Briefly, 20 mg of pYAL-B35(HIV) was used as a template for the error-prone mutazyme II reaction. This product was amplified to generate 50 mg of insert DNA. Libraries were created by electroporation of chemically competent EBY100 with mutagenized insert and 10 mg of linearized pYAL vector. Successful homologous recombination of the insert with parental vector was verified by sanger sequencing (Sequetech). The error rate of the library was $3 amino acid mutations per Kb. Selections were performed as described below. Functional surface expression was obtained following a single mutation, S116F (Figure S4 ). This mutation, in the F-pocket, is found in other B35 alleles such as HLA B35*03 and B35*06 (https://www.ebi.ac.uk/ipd/imgt/hla/). B35-peptide yeast display libraries were created as previously reported (Birnbaum et al., 2014) . Briefly, primers allowing all 20 amino acids via NNK codons at all peptide positions except the defined anchors (https://doi.org/10.17632/sgff3j9sbg.1). The libraries allowed for limited diversity at P2 and P9 to maximize the number of correctly folded pMHC clones on the surface of yeast. pMHC libraries were generated by electroporation of chemically competent EBY-100 cells via homologous recombination of linearized pYAL vector and library containing single chain trimer pMHC construct, the heavy chain was modified with a Y84A mutation to allow for the peptide to thread through the MHC groove as well as the selected S116F mutation described above. The final library had a diversity of about 2 3 10 8 yeast transformants which was determined by colony counting after limited dilutions.
Yeast were passaged in SDCAA and induced with SGCAA and selected with streptavidin (SA) -coated magnetic MACS beads (Miltenyi) coated with biotinylated TCR. The number of yeast used for each round of selection was 10x the diversity of library from the previous selection step (for round 1 selection 10x the library diversity). First, yeast were incubated on a rotator at 4 C for 1 hour in 10 mL of PBS+ 0.5% bovine serum albumin and 1 mM EDTA (PBE) with 250 ml of SA beads. Yeast-bead mixture was negatively selected by passing through an LS Column (Miltenyi) attached to a magnetic stand (Miltenyi) and washed 3 times with PBE while the flow through was collected. The elution from the column contained yeast clones that non-specifically bound to the beads. The flow through was subsequently incubated with 250 ml SA beads preincubated with 400 nM of TCR for 3 hours at 4 C on a rotator. The yeast were washed and centrifuged at 5000 g for 1 minute. The yeast -TCR coated bead mixture was resuspended in 5 mL of PBE and was then passed over a new LS column and the subsequent elution from the column was grown in 3 mLs of SDCAA pH 4.5 overnight. Once the yeast reached OD > 2, they were induced in SGCAA for 2-3 days before the next round of selection. Rounds 2 and 3 were done used 50 ml of SA-beads or TCR coated beads in 500 ml of PBE. The fourth round of selection was performed by first doing a negative selection with 400 nM streptavidin-647 (SA-647) in 500 ml for 1 hr at 4 C, followed by a 20 minute incubation with 50 ml of microbeads coated with anti-647 (miltenyi). The positive selection was performed by incubating the yeast for 3 hr at 4 C with 400 nM TCR tetramer followed by 20 minutes of incubation with anti-647 beads. All rounds were monitored with anti-c-myc (Cell Signaling) staining which was done for 1 hr on ice. Primers for creation of error prone and peptide libraries can be found at https://doi.org/10. 17632/sgff3j9sbg.1.
Deep sequencing DNA was isolated from each round of selection using the a Zymoprep II Kit (Zymo Research). 5 3 10 7 yeast from each round were lysed and DNA was extracted. Individual barcodes and random 8-mer sequences were encoded by PCR primers. These primers amplified the peptide of the construct through the middle of b2m. These PCR products were extracted and subsequently amplified adding the Illumina chip primer sequences to generate the final products. These produces encoded (5 0 -3 0 ) P5 Truseq read -1-N8-barcode-pMHC-(N 8 )-P7-2 Illumina Truseq read. The library was purified by agarose gel purification and quantified by nanodrop and BioAnalyzer (Agilent Genomics). The library was deep sequenced by Illumina Miseq sequencer using either a 2x150 V2 or V3 kit for a low diversity library. Primers used for barcoding can be found at https://doi.org/10.17632/sgff3j9sbg.1.
Analysis of deep sequencing data
Paired-end reads were determined from the deep sequencing results using PandaSeq (Masella et al., 2012) . Paired-end reads are parsed by barcode using Geneious V6 to identify the round of selection. All nucleotide sequences with less than 10 counts in rounds 3 and 4 of the selection and which differed by only 1 nucleotide sequence from another sequence in the round were coalesced to the dominant sequence. Any data with frameshifts or stop codons were removed from further analysis. Sequences were processed using custom Perl scripts and shell commands.
Hamming distances were calculated using MATLAB (Mathworks Inc.) by iterating through each peptide against all other peptides from the selected round 3 library sequences. The output score generated is the number of matching amino acid positions between peptides.
Crystallization and X-ray data collection For the TCR589-B35-HIV complex, TCR589 was expressed using baculovirus and B35-HIV was refolded and purified separately, as described above. The TCR was treated with 3C protease and carboxypeptidases A and B. TCR589 and B35-HIV were mixed at a 1:1 molar ratio and concentrated to 13 mg/ml. Crystals formed in 100 nl sitting drops in 0.1 M Tris pH 8.0, 20% PEG 3350, 0.002M ZnCl.
For both the TCR55 complexes, the TCR was refolded and purified as described above. The TCR and pMHC of interest were mixed at a 1:1 ratio and concentrated to 11 mg/ml. Crystals of the TCR55-HIV-B35 complex formed in 100 nL sitting drops in PEG 4000, 0.1 M sodium cacodylate, pH 6.0, 0.2 M (NH 4 )2SO 4 from the TOPS Screen (Bulek et al., 2012) . For the TCR55-Pep20-B35, crystals formed in sitting drops in 0.04 M KH 2 PO 4 , 16% w/v PEG 8000, 20% v/v Glycerol.
All crystals were flash frozen in liquid nitrogen in 25% ethylene glycol + mother liquor. Datasets for the 589-B35-HIV complex and 55-B35-Pep20 complex were collected at Stanford Synchrotron Radiation Lightsource (Stanford, CA, USA) beamline 12-2. The datasets for the TCR55-HIV-complex was collected at Advanced Light Source (Berkeley, CA, USA) at beamline 8.2.2. Data were indexed, integrated and scaled using either XDS/XSCALE or the HKL-2000 program suite (http://www.hkl-xray.com/) (Kabsch, 2010).
Structure determination and refinement All structures were solved using molecular replacement using the program Phaser (McCoy, 2007) . The molecular replacement search model for B35 was an unliganded B35 molecule and b2m as separate chains (1A1N). For TCR589a the alpha chain of the SB27 TCR (PDBID: 2AK4), and for the TCR589b the beta chain of the SB47 TCR was used (PDBID: 4JRY) as search models. For the TCR55a chain, the search model was the alpha chain of the 9c2 TCR (PDBID: 4LFH). For the TCR55b, the search model was the beta chain of the MR1 TCR (PDBID: 4PJ5). For the TCR55-Pep20-B35 complex the solved TCR55 structure was used as a search model. For all TCR chains the CDR3 was deleted to avoid model bias. Manual model building of the peptide and the CDR3 loops was done in COOT followed by iterative rounds of refinement with Phenix (Adams et al., 2010) (https://www.phenix-online.org/), using TLS constraints for the 589-HIV-B35 structure. Figures were made with PYMOL (https://pymol.org/2/). Structures have been deposited in the RCSB protein data bank with accession codes 6BJ3, 6BJ2, and 6BJ8.
Computational methods for MD simulations
For the TCR55-B35(HIV) and TCR55-B35(Pep20) systems, the crystallographic coordinates of the TCR55 Va and b domains (residues 3-112 in chain D and residues 4-115 in chain H), HLA-B35 a1-2 domains (residues 3-180 in chain A), antigen (chain C) and structural waters were taken from the PDB files which have additional domains including TCR55 Cab, HLA-B35a3 and b2M. AmberTools16 was used to add hydrogen atoms to the heavy-atom only crystallographic coordinates. A capping acetyl group (ACE) was added to every N-term truncated in the middle of a protein domain. An N-methyl amide capping group (NME) was added to every C-term truncated in the middle of a protein domain. The TCR55(Vab)-antigen-B35(a1-2) system was oriented such that the N-term to C-term antigen axis (the +x shear direction defined in the main text) was aligned in the +z direction of the simulation box. The oriented protein complex together with the structural waters were then solvated in a water box of 93 3 83 3 113 Å 3 pre-equilibrated water molecules, where enough room was left out in the +z direction for shearing. Na + and Cl À ions were added to balance out the net charge of the protein complex and also to set the NaCl concentration to 154 mM. The above processes were done with AmberTools16 (Case et al., 2018) . The final simulation box contained about 80,000 atoms. The MD simulations were performed using NAMD version 2.12 (http://www.ks.uiuc.edu/Research/namd/) . The following parameters were used for the common part of setting up the MD simulations: Amber ffSB14 force field for protein (Maier et al., 2015) and TIP3P force field for explicit water solvent, particle mesh Ewald method for periodic boundary conditions, 9 Å cut-off distance for van der Waals and electrostatic interactions, 11 Å between pairs of atoms for inclusion in pair lists that are used to calculate van der Waals and electrostatic interactions, 1 fs integration time step, Langevin thermostat at 310 K and Nosé -Hoover Langevin piston pressure at 1 atm for simulating the NPT ensemble. To relax the initialized protein-solvent interface created in the simulation box, each TCR55(Vab)-antigen-B35(a1-2) system underwent the following series of simulations: 30,000 steps of minimization and 10 ns of NPT simulation with the atoms of the protein complex fixed, followed by 5 ns of NPT simulation with all atoms free.
Gaussian Accelerated Molecular Dynamics (GaMD) were used to explore the conformational space of the TCR-pMHC system for Pep20 antigen with and without external force (Miao et al., 2015) . NAMD version Git-2017-11-28 was used for the GaMD simulation (Pang et al., 2017) . GaMD is an unconstrained enhanced sampling method which adds a harmonic boost potential to smoothen the potential energy surface of the simulation system. For our purpose, only GaMD was used to reveal distinct structural flexibility and identify proper collective variables, instead of obtaining free energy profiles through reweighting an extensive GaMD simulation.
A concise description of the GaMD methodology is given here that introduces the module of the method that we used for our purpose. For a system of N atoms r ! = fr 1 ;.;r N g, GaMD sets a threshold energy E in comparison with the total potential Vð r ! Þ to determine a boost potential DVð r ! Þ which is added on top of Vð r ! Þ during the GaMD simulation:
DVð r ! Þ = where k is the harmonic force constant. In determining the two adjustable parameters E and k, 1 ns of preparatory conventional MD was run to collect the maximum, minimum, average and standard deviation of the system potential energies V max , V min , V avg , and s V during the 1 ns simulation. The following formula was used to determine E and k:
; where s 0 = 6:0 kcal=mol;
which correspond to the default values in setting up the GaMD calculation in NAMD. 25 ns GaMD simulations for TCR55-Pep20-B35 system were run with and without external force respectively and collected the trajectories of several collective variables, including the orientation of the TCR about the pMHC assembly (the azimuthal angle 4), the vector components between the center of masses of TCR and MHC, and several salt-bridges and hydrogen bonds that are present in the crystal structure or formed during the GaMD simulations (Fiorin et al., 2013) . These sampled data of collective variables were used for Principal Component Analysis (PCA) (Maisuradze et al., 2009) . Dim1 which shares the most information with the azimuthal angle 4 and Dim2 which shares the most information with the salt-bridge CDR2a-Glu55 and MHCa2-Arg157 are the top two principal components that capture most of the covariance (https://doi.org/10.17632/sgff3j9sbg.1).
The azimuthal angle 4 and the Glu55-Arg157 salt-bridge was used as the collective variables (CV) for the free energy sampling using Adaptive Biasing Force (ABF) method (Darve et al., 2008; Hé nin et al., 2010) . The biasing force was applied to these two CVs. The potential of mean force (PMF) as a function of these two CVs were calculated by integrating the reversible work done by the mean force from the accumulated force measurements in the CV space: À12 to 8 for the azimuthal angle 4 in bins of 0.5 , 3.5 Å to 13.5 Å for the Glu55-Arg157 salt-bridge in bins of 0.2 Å . The number of samples in a bin prior to application of the ABF was set to 10,000. The maximum magnitude of the ABF force for both CVs was set to 10, where the unit of force is kcal/mol divided by the respective CV unit. 50 ns MD simulation for each case was performed and convergence of the free energy was checked.
After obtaining the free energy minima from the ABF sampling as the starting points, shearing simulation was performed by steered molecular dynamics (SMD) (Isralewitz et al., 2001) . Constant velocity SMD simulations have been used by other researchers to study the molecular mechanism of catch bond formation (Lou and Zhu, 2007; Manibog et al., 2014) . Constant velocity SMD was used to shear the center of mass of TCR Vab in the +x direction, relative to the MHC. Here, +x is defined as the axis of the peptide pointing toward the C terminus ( Figure 7D ). The center of mass of TCR Vab is attached via a harmonic spring with force constant 1.0 kcal/mol/Å 2 to a point in space that is pulled at constant velocity of 20 Å /ns along the +x direction. The SMD simulation was run over a period of 2 ns, leading to a total displacement of 40 Å in the range of x z 10 -50 Å , where x z 10 Å at the starting point. For -x, ± y, and ± z direction, SMD simulations with a constant velocity of 20 Å /ns and an external force of 13.9 pN applied along the respective axis were performed till the TCR reaches the boundary of the simulation box.
Assembling starting structures for steered MD Starting with the relaxed crystal structure of TCR55-B35(Pep20) (denoted Pep20 xtal ) the ABF sampling method was applied under a constant external force of 13.9 pN applied in the +x direction. The magnitude of the external force is not strong enough to cause dissociation between TCR-pMHC or lead to a net displacement along the +x direction. The sampling under external force gave rise to the energy minimized structure Pep20 min , which differs from the crystal structure (Pep20 xtal with 4 = 0 and r SB = 7.5 Å ) in that 4 = À2 and r SB = 3.9 Å and by 1.22 Å RMSD (https://doi.org/10.17632/sgff3j9sbg.1). Pep20 min does not have the following direct hydrogen bonds that are present in Pep20 xtal : P4(Thr) with CDR1a Ser31, P6(Asp) and Tyr74 at the MHC b sheet groove base.
For TCR55-B35(HIV), the same procedure yielded HIV min . An alternative starting structure for the HIV system was obtained by mutating Pep20 min to HIV in silico, and is denoted as HIV mut . The shearing simulation that started from HIV mut also revealed slip bonds (see Mendeley Data). For TCR55-B35(SQL), the same alternative procedure yielded SQL mut . Pep20 min , HIV min , HIV mut and SQL mut are starting points for shearing the TCR with respect to the MHC to assess the integrity of the TCR-antigen interactions. Pep20 min and HIV min followed the same procedure of free-energy sampling from their respective crystal structure. No crystal structure is available for the SQL system, therefore we obtained SQL mut by mutating the peptide from Pep20 min to SQL and minimizing the complex. We also obtained HIV mut by this alternative procedure to show the lack of a catch bonds does not depend on the starting point (https:// doi.org/10.17632/sgff3j9sbg.1).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data are expressed as the mean ± the standard deviation (SD) (for technical replicates) or mean ± the standard error of the mean (SEM) (for biological replicates), is stated in the figure legends, results, and methods details. The exact value of n and what n represents (e.g., number of cells, single molecule ligand binding events or experimental replicates) is stated in figure legends and results. All data except dwell time measurements (in methods details and below) were plotted and analyzed in Prism.
Data related to CD69 and pERK assays (Figures 3, 5, and Figures S3 and S5) . Data were analyzed using Flowjo to gate live, CD3+ SKW3 cells. The mean MFI expression of CD69 and pERK of CD3+ cells is reported. All measurements were done in biological and technical triplicate, only one representative biological triplicate is shown. SD (n = 3) are used and listed in the figure legends. EC 50 was calculated in Prism using a non-linear fit of log(agonist) versus dose response. The r 2 for KD versus EC 50 was calculated in prism using a linear regression.
Zap70 clustering (Figure 3 ). The percent of cells that clustered was calculated by manual scoring of cells which were randomly selected, the error reported is the standard deviation for 2 pooled biological duplicates. Total number of cells reported in figure legend.
The percent of GUVs that separated CD45 were calculated by manual scoring of GUVs that were randomly selected, the error reported is the SEM for biological triplicates. Total number of GUVs analyzed are reported in figure legend.
Dwell time measurements (Figure 2 and Figure S6 ). Single molecule diffraction-limited spots were detected in raw .tif image stacks of pMHC-647N and filtered by size and intensity. Spot detections and linking were done with the TrackMate plugin for ImageJ. Size and intensity thresholds were first determined by eye using a test dataset and then applied uniformly to all data collected with the same imaging conditions. The dwell time distributions are roughly exponential, with the bleaching rate being approximately 20 times slower than the observed dwell events. For each measurement four individual cells, with hundreds of tracks per cell were analyzed. Further plotting and analysis were done with in-house developed Python scripts.
BFP Force Experiments (Figure 6 ). Mean bond lifetimes were calculated from hundreds of measurements over a number of days (TCR55-p20 (749 lifetimes), TCR55-SQL (574 lifetimes), TCR589-HIV (571 lifetimes), TCR55-HIV (560 lifetimes)). All forces were measured on each day. Beads were coupled with pMHC to allow for $10% adhesion frequency. SEM for measurements at each force are reported and were plotted in Prism.
DATA AND SOFTWARE AND AVAILABILITY
Deep Sequencing
Deep sequencing of TCR55 selections of pMHC yeast display libraries are available in the sequence read archive under accession number SAMN08689057.
Structures
Structures described here have been deposited in the PDB with the accession numbers PDB: 6BJ2, 6BJ3, and 6BJ8. 
